Na+/H+ exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain

Cardiovasc Res. 2008 Nov 1;80(2):255-62. doi: 10.1093/cvr/cvn179. Epub 2008 Jun 30.

Abstract

Aims: Recent studies have reported that the calcium-dependent protease calpain is involved in hyperglycaemia-induced endothelial dysfunction and that the Na(+)/H(+) exchanger (NHE) is responsible for an increase in the intracellular calcium (Ca(2+)(i)) concentration in diabetes. We hypothesized that activation of NHE mediates hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain.

Methods and results: Exposure of human umbilical vein endothelial cells (HUVECs) to high glucose (HG, 30 mM d-glucose) time dependently increased both the Ca(2+)(i) concentration and calpain activity. Chelation of free Ca(2+)(i) with 1,2-bis (2-aminophenoxy) ethane-N, N, N',N'-tetraacetic acid abolished the HG-increased calpain activity. In addition, HG activated NHE in a time-dependent manner, but cariporide, an NHE inhibitor, blocked the HG-induced increase in NHE activity. Furthermore, cariporide or NHE siRNA (small interfering ribonucleic acid) attenuated the HG-induced increases of both Ca(2+)(i) concentration and calpain activity. All of these HG-induced effects in HUVECs, including decreased endothelial nitric oxide synthase (eNOS) activity and NO (nitric oxide) production and increased dissociation of heat shock protein (hsp90) from eNOS, were NHE or calpain reversible. In vivo experiments showed that cariporide treatment via inhibition of NHE activity significantly attenuated the hyperglycaemia-induced impairment of acetylcholine-induced endothelium-dependent relaxation in streptozotocin-injected diabetic rats.

Conclusion: Activation of NHE via calcium-dependent calpain contributes to hyperglycaemia-induced endothelial dysfunction through dissociation of hsp90 from eNOS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium / metabolism
  • Calpain / antagonists & inhibitors
  • Calpain / metabolism*
  • Cells, Cultured
  • Chelating Agents / pharmacology
  • Cysteine Proteinase Inhibitors / pharmacology
  • Diabetes Mellitus, Experimental / enzymology*
  • Diabetes Mellitus, Experimental / physiopathology
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / enzymology*
  • Endothelium, Vascular / physiopathology
  • Glucose / metabolism
  • Guanidines / pharmacology
  • HSP90 Heat-Shock Proteins / metabolism
  • Humans
  • Hyperglycemia / enzymology*
  • Hyperglycemia / physiopathology
  • Male
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Nitric Oxide Synthase Type III
  • RNA Interference
  • RNA, Small Interfering / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Sodium-Hydrogen Exchangers / antagonists & inhibitors
  • Sodium-Hydrogen Exchangers / genetics
  • Sodium-Hydrogen Exchangers / metabolism*
  • Sulfones / pharmacology
  • Time Factors
  • Vasodilation* / drug effects
  • Vasodilator Agents / pharmacology

Substances

  • Chelating Agents
  • Cysteine Proteinase Inhibitors
  • Guanidines
  • HSP90 Heat-Shock Proteins
  • RNA, Small Interfering
  • Sodium-Hydrogen Exchangers
  • Sulfones
  • Vasodilator Agents
  • Nitric Oxide
  • cariporide
  • Nitric Oxide Synthase Type II
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • Calpain
  • Glucose
  • Calcium